Contributing Member of the Healthcare Councils
Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.
GLG News by this Author
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Lung cancer profiling- May lead to improvements in care! Implications for Genentech & others.
July 3, 2008
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells | content.nejm.org
We may be able to analyze EGFR mutations from periperal blood of lung cancer patients. Very frequently enough tissue fromm needle biopsies are not available for analysis. This may replace the need for new biopsies.
-
Amgen/Oral VEGF Inhibitor/Implications??? Interesting future!
July 3, 2008
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer | content.nejm.org
This oral Vascular Endothelial Growth Factor (VEGF) inhibitor appears to have activity in radioresistant differentiated thyroid carcinoma.
-
The heck with the impact on Roche. How about the patients??
June 30, 2008
Roche decision denies cancer drug to Britons | www.ft.com
Patients who wish to receive Avastin for breast and lung Cancer will need to pay for it themselves.
-
How are we to pay for computers with a 10% drop in Medicare fees?
June 30, 2008
Medicare fees to doctors fall Tuesday | news.yahoo.com
Rising costs for care of seniors in physician offices will be made more painful by the reimbursement cuts. Will it impede care of seniors??
-
The other shoe falls II: Amgen and J & J will not be happy.
June 27, 2008
Europe Backs Anemia-Drug Warnings | online.wsj.com
Due to possible tumor growth warnings will be attached to the use of erythropoietin agents.
-
Bayer and J &J in the propylactic anticoagulation market. GSK (Lovenox) beware!
June 26, 2008
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty | content.nejm.org
This paper as well as http://content.nejm.org/cgi/content/full/358/26/2765 report the efficacy of an oral anticoagulant type drug that appears to be better & safer than parenteral low molecular weight heparin (LMWH).
-
Amgen as well as J & J: Adding insult to injury......
June 23, 2008
New Study Probes Safety of Erythropoiesis-Stimulating Agents | www.medscape.com
Safety concerns continue to be voiced re: the effect of erythropoietin products (Epos) on tumor growth.
-
Electronic Records?? Great but.......
June 20, 2008
Most Doctors Aren’t Using Electronic Health Records | www.nytimes.com
Only 1 in 5 physicians use electronic patient records. ( and those are either in University Hospitals, large multispecialty clinics or VA hospitals)
-
GSK is going after Genentech's (Herceptin) Cookies....
June 19, 2008
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer | jco.ascopubs.org
Lapatinib, an oral HER-2 inhibitor, is effective in monotherapy in HER-2+ metastatic breast cancer.
-
Melanoma: The Holy Grail at Last??
June 19, 2008
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 | content.nejm.org
"In summary, THEY showed that the infusion of a clonal population of CD4+ T cells with specificity for a single tumor-associated antigen caused complete regression of a tumor. During regression of the tumor, this clone appears to have induced the patient's own T cells to respond to other antigens of his tumor. These findings support further clinical studies of antigen-specific CD4+ T cells in the treatment of malignant disease."
-
Targeted therapy for myeloproliferative disorders (MPD) from Cephalon
June 11, 2008
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders | bloodjournal.hematologylibrary.org
Very preliminary but this agent may offer a targeted, more "natural" approach to the MPD's- Polycythemia Vera, Myelofibrosis and Primary thrombocytosis.
-
Diabetes: Let's avoid pseudoscience and start over.....
June 9, 2008
Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Tight Glucose control in type 2 diabetes mellitus did not result in improved survival and possibly had a negative impact.
-
Trovax(R) Sanofi-Aventis and Oxford Biomedica: Interesting but.....
June 4, 2008
Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer | www.pipelinereview.com
This immunotherapeutic agent in association with interleukin 2 or interferon may be effective in renal cell carcinoma (RCC). To be tested in a phase III trial (against what??)
-
ASA404 in a phase III trial in lung cancer?? "A crap shoot?"
June 4, 2008
Positive data on Antisoma’s ASA404 presented at ASCO | www.pipelinereview.com
That appears to be a well contructed phase III trial adds ASA404 or a placebo to Taxol/Carboplatin. Nothing exotic, endpoints are overall survival (OS) as well as OS in Squams and non Squams.
-
A New Algorithm Will be Needed to Calculate Market Sharee
June 2, 2008
Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Genetic profiling will tell us who should or should not receive particular anti neoplastic agents. This is "personalized" therapy that has been predicted x years.
-
ImClone: One study shot down. The other??
June 2, 2008
Drug Brings ImClone in From Cold | online.wsj.com
Well we know that the lung cancer trial http://online.wsj.com/article/SB121227163771635641.html?mod=2_1566_topbox was a bust so far. What other "good news" do we await
-
Erbitux (ImClone):1 month and <10% additional survival in lung cancer. Not very impressive!
June 2, 2008
Erbitux Slightly Boosts Survival in Cancer Study | online.wsj.com
Basically?? It's a bust until we see subset analysis. It is possible adenocarcinomas as well as non smokers will show better survival
-
Revlimid (Celgene) in CLL- not a bad addition in our therapeutic algorithm
May 27, 2008
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia | bloodjournal.hematologylibrary.org
Revlimid has activity in Chronic Lymphatic Leukemia (CLL) in addition to myeloma and myelodysplasia.
-
So much for non-invasive surgery in prostate cancer
May 27, 2008
Mixed Outcomes in Laparoscopy for Prostates | www.nytimes.com
Higher recurrance rate???!!!
-
May 27, 2008
Hints of Progress in Drugs Treating Brain Cancer | www.nytimes.com
While no slam dunk cures are noted, drugs such as Avastin (Genentech), Temodar (Schering-Plough) & Avant/Pfizer vaccines are making an impact on "Brain Cancer" survival.
- Subscribe to Updates
-
This author consults with leading institutions through GLG
Most Popular Healthcare News
-
February 7, 2012
-
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
-
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
-
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
-
Medtech M&A activity accelerates in 2011
November 30, 2011
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.